2 completed, 1 recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Recruiting 1 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial nilotinib - Chronic Myelogenous Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 19 | 2008-12-01 | 2016-11-16 |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cyclophosphamide - Anemia, Graft Versus Host Disease | Phase 4 | Completed | University of Maryland, Baltimore | 45 | 1998-09-01 | 2019-10-17 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Anemia (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1)
Bone Marrow Diseases (3) · Carcinogenesis (3) · Cell Transformation, Neoplastic (3) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Leukemia (2) · Myeloproliferative Disorders (2)
nilotinib (2) · Antilymphocyte Serum (1) · Cyclophosphamide (1) · Dasatinib (1) · Filgrastim (1) · Imatinib Mesylate (1) · Radiotherapy (1) · Thiotepa (1) · asciminib (1) · bosutinib (1)
Novartis Pharmaceuticals (2) · University of Maryland, Baltimore (1)
Poland (2) · United States (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Lebanon (1)
2023 (1)